PL1896507T3 - Przeciwciała monoklonalne anty-CD71 i ich zastosowanie do leczenia złośliwych komórek nowotworowych - Google Patents
Przeciwciała monoklonalne anty-CD71 i ich zastosowanie do leczenia złośliwych komórek nowotworowychInfo
- Publication number
- PL1896507T3 PL1896507T3 PL06795343T PL06795343T PL1896507T3 PL 1896507 T3 PL1896507 T3 PL 1896507T3 PL 06795343 T PL06795343 T PL 06795343T PL 06795343 T PL06795343 T PL 06795343T PL 1896507 T3 PL1896507 T3 PL 1896507T3
- Authority
- PL
- Poland
- Prior art keywords
- monoclonal antibodies
- malignant tumour
- tumour cells
- treating malignant
- cells
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2881—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Transplantation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/154,262 US7736647B2 (en) | 2005-06-15 | 2005-06-15 | Anti-CD71 monoclonal antibodies and uses thereof for treating malignant tumor cells |
PCT/IB2006/002331 WO2007000671A2 (en) | 2005-06-15 | 2006-06-14 | Anti-cd71 monoclonal antibodies and uses thereof for treating malignant tumour cells |
EP06795343A EP1896507B1 (en) | 2005-06-15 | 2006-06-14 | Anti-cd71 monoclonal antibodies and uses thereof for treating malignant tumour cells |
Publications (1)
Publication Number | Publication Date |
---|---|
PL1896507T3 true PL1896507T3 (pl) | 2010-08-31 |
Family
ID=37573538
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL06795343T PL1896507T3 (pl) | 2005-06-15 | 2006-06-14 | Przeciwciała monoklonalne anty-CD71 i ich zastosowanie do leczenia złośliwych komórek nowotworowych |
Country Status (10)
Country | Link |
---|---|
US (2) | US7736647B2 (pl) |
EP (1) | EP1896507B1 (pl) |
JP (1) | JP5185815B2 (pl) |
AT (1) | ATE459653T1 (pl) |
CA (1) | CA2612486A1 (pl) |
DE (1) | DE602006012672D1 (pl) |
DK (1) | DK1896507T3 (pl) |
ES (1) | ES2341625T3 (pl) |
PL (1) | PL1896507T3 (pl) |
WO (1) | WO2007000671A2 (pl) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20110074879A (ko) * | 2008-10-23 | 2011-07-04 | 에프. 호프만-라 로슈 아게 | 면역글로불린을 암호화하는 핵산의 측정 방법 |
RU2704802C2 (ru) * | 2009-07-22 | 2019-10-31 | Актиниум Фармасьютикалз Инк. | Способы получения радиоиммуноконъюгатов |
WO2011130164A2 (en) * | 2010-04-13 | 2011-10-20 | The Regents Of The University Of California | Unconjugated anti-tfr antibodies and compositions thereof for the treatment of cancer |
FR2959416B1 (fr) * | 2010-05-03 | 2012-06-22 | Monoclonal Antibodies Therapeutics Mat Biopharma | Utilisation d'anticorps anti-cd71 pour la preparation d'un medicament |
PT2646470T (pt) | 2010-11-30 | 2017-05-03 | Hoffmann La Roche | Anticorpos anti-recetor da transferrina de baixa afinidade e a sua utilização na transferência de scfv terapêuticos através da barreira hematoencefálica |
US9623117B2 (en) * | 2011-04-04 | 2017-04-18 | Wisconsin Alumni Research Foundation | Method for selective targeting and entry of bacterial toxins to cells |
JP2014518615A (ja) * | 2011-04-22 | 2014-08-07 | エマージェント プロダクト デベロップメント シアトル, エルエルシー | 前立腺特異的膜抗原結合タンパク質および関連組成物ならびに方法 |
US9696312B2 (en) | 2011-09-02 | 2017-07-04 | The Trustees Of Columbia University In The City Of New York | Diagnosis and treatment of cancer expressing ILT3 or ILT3 ligand |
SG11201401518TA (en) | 2011-10-28 | 2014-05-29 | Teva Pharmaceuticals Australia Pty Ltd | Polypeptide constructs and uses thereof |
CN104662044B (zh) | 2012-08-24 | 2018-10-30 | 加利福尼亚大学董事会 | 用于治疗ror1癌症并抑制转移的抗体和疫苗 |
AU2016258988A1 (en) | 2015-05-04 | 2017-12-07 | Cytomx Therapeutics, Inc | Anti-ITGa3 antibodies, activatable anti-ITGa3 antibodies, and methods of use thereof |
BR112017023862A2 (pt) | 2015-05-04 | 2018-07-17 | Cytomx Therapeutics Inc | anticorpos anti-cd71, anticorpos anti-cd71 ativáveis, e métodos de uso destes |
EP3325006A4 (en) | 2015-07-17 | 2019-03-06 | The Trustees of Columbia University in the City of New York | METHOD FOR TREATING CD166-EXPRESSIVE CANCER |
EP3352760A4 (en) | 2015-09-21 | 2019-03-06 | Aptevo Research and Development LLC | CD3 BINDING POLYPEPTIDES |
CA3014934A1 (en) | 2016-03-04 | 2017-09-08 | JN Biosciences, LLC | Antibodies to tigit |
MA45328A (fr) * | 2016-04-01 | 2019-02-06 | Avidity Biosciences Llc | Compositions acide nucléique-polypeptide et utilisations de celles-ci |
US20190240346A1 (en) | 2016-06-20 | 2019-08-08 | Genahead Bio, Inc. | Antibody-drug conjugate |
IL299099A (en) | 2016-06-27 | 2023-02-01 | Univ California | Combinations of cancer treatments |
US10597438B2 (en) | 2016-12-14 | 2020-03-24 | Janssen Biotech, Inc. | PD-L1 binding fibronectin type III domains |
WO2018111978A1 (en) | 2016-12-14 | 2018-06-21 | Janssen Biotech, Inc. | Cd137 binding fibronectin type iii domains |
CA3046963A1 (en) | 2016-12-14 | 2018-06-21 | Janssen Biotech, Inc. | Cd8a-binding fibronectin type iii domains |
SG11201906200WA (en) | 2017-01-06 | 2019-08-27 | Avidity Biosciences Llc | Nucleic acid-polypeptide compositions and methods of inducing exon skipping |
WO2018165619A1 (en) | 2017-03-09 | 2018-09-13 | Cytomx Therapeutics, Inc. | Cd147 antibodies, activatable cd147 antibodies, and methods of making and use thereof |
GB201711809D0 (en) | 2017-07-21 | 2017-09-06 | Governors Of The Univ Of Alberta | Antisense oligonucleotide |
EP3762420A1 (en) | 2018-03-09 | 2021-01-13 | CytomX Therapeutics, Inc. | Activatable cd147 antibodies and methods of making and use thereof |
KR102258015B1 (ko) * | 2019-05-15 | 2021-05-27 | 강원대학교 산학협력단 | 암 줄기세포 세포막 단백질에 특이적인 항체 및 그 응용 |
KR102258014B1 (ko) * | 2019-05-15 | 2021-05-27 | 강원대학교 산학협력단 | 암 줄기세포 세포막 단백질에 특이적인 항체 및 그 응용 |
KR20220041851A (ko) * | 2019-07-19 | 2022-04-01 | 우시 바이올로직스 아일랜드 리미티드 | 접합을 위한 폴리펩티드 복합체 및 이의 용도 |
WO2021061867A1 (en) | 2019-09-23 | 2021-04-01 | Cytomx Therapeutics, Inc. | Anti-cd47 antibodies, activatable anti-cd47 antibodies, and methods of use thereof |
WO2021076546A1 (en) * | 2019-10-14 | 2021-04-22 | Aro Biotherapeutics Company | Cd71 binding fibronectin type iii domains |
US11781138B2 (en) | 2019-10-14 | 2023-10-10 | Aro Biotherapeutics Company | FN3 domain-siRNA conjugates and uses thereof |
US11820824B2 (en) | 2020-06-02 | 2023-11-21 | Arcus Biosciences, Inc. | Antibodies to TIGIT |
BR112023021325A2 (pt) | 2021-04-14 | 2023-12-19 | Aro Biotherapeutics Company | Domínios de fibronectina tipo iii de ligação a cd71 |
MX2024002753A (es) | 2021-09-01 | 2024-05-20 | Biogen Ma Inc | Anticuerpos anti receptor de transferrina y usos de los mismos. |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5308626A (en) | 1985-06-28 | 1994-05-03 | Toni N. Mariani | Lymphokine activated effector cells for antibody-dependent cellular cytotoxicity (ADCC) treatment of cancer and other diseases |
CA2081368A1 (en) | 1990-03-27 | 1991-09-28 | Ian S. Trowbridge | Method for inhibiting cell growth and compositions useful therefor |
US5762932A (en) * | 1990-04-26 | 1998-06-09 | University Of Iowa Research Foundation | Combined treatment of iron depletion and IgG antibody |
US6107090A (en) * | 1996-05-06 | 2000-08-22 | Cornell Research Foundation, Inc. | Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains |
CA2569692C (en) | 2004-06-07 | 2015-07-21 | Raven Biotechnologies, Inc. | Transferrin receptor antibodies |
-
2005
- 2005-06-15 US US11/154,262 patent/US7736647B2/en not_active Expired - Fee Related
-
2006
- 2006-06-14 JP JP2008516448A patent/JP5185815B2/ja not_active Expired - Fee Related
- 2006-06-14 DE DE602006012672T patent/DE602006012672D1/de active Active
- 2006-06-14 CA CA002612486A patent/CA2612486A1/en not_active Abandoned
- 2006-06-14 WO PCT/IB2006/002331 patent/WO2007000671A2/en active Application Filing
- 2006-06-14 EP EP06795343A patent/EP1896507B1/en not_active Not-in-force
- 2006-06-14 AT AT06795343T patent/ATE459653T1/de active
- 2006-06-14 PL PL06795343T patent/PL1896507T3/pl unknown
- 2006-06-14 DK DK06795343.0T patent/DK1896507T3/da active
- 2006-06-14 ES ES06795343T patent/ES2341625T3/es active Active
- 2006-06-14 US US11/922,025 patent/US8409573B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US8409573B2 (en) | 2013-04-02 |
DE602006012672D1 (de) | 2010-04-15 |
ES2341625T3 (es) | 2010-06-23 |
EP1896507A2 (en) | 2008-03-12 |
DK1896507T3 (da) | 2010-06-07 |
WO2007000671A2 (en) | 2007-01-04 |
WO2007000671A3 (en) | 2007-04-26 |
JP2009509497A (ja) | 2009-03-12 |
ATE459653T1 (de) | 2010-03-15 |
EP1896507B1 (en) | 2010-03-03 |
US20110311544A1 (en) | 2011-12-22 |
US7736647B2 (en) | 2010-06-15 |
JP5185815B2 (ja) | 2013-04-17 |
CA2612486A1 (en) | 2007-01-04 |
US20060286030A1 (en) | 2006-12-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PL1896507T3 (pl) | Przeciwciała monoklonalne anty-CD71 i ich zastosowanie do leczenia złośliwych komórek nowotworowych | |
IL258880A (en) | Compounds of diarylhydantoin | |
SG171690A1 (en) | Treatment of protein degradation disorders | |
TW200740844A (en) | Novel MAdCAM antibodies | |
WO2006107451A3 (en) | Honokiol derivatives for the treatment of proliferative disorders | |
WO2006029219A3 (en) | Human monoclonal anti-ctla4 antibodies in cancer treatment | |
UA94707C2 (en) | Antigen-binding molecule capable of binding to plgf | |
MX2010005022A (es) | Anticuerpos que unen celulas dendriticas y epiteliales 205 (dec-205) humanas. | |
UA101478C2 (ru) | Соединения, полезные как ингибиторы raf-киназы | |
MX2020011789A (es) | Anticuerpos monoclonales contra claudina-18 para el tratamiento de cancer. | |
MX2009005455A (es) | (r)-n-estereoisomeros de analogos de 7,8-saturados-4,5 epoxi-morfinano. | |
MX2011006959A (es) | Compuestos substituidos de 5,6-dihidro-6-fenilbenzo [f] isoquinolina-2-amina. | |
TNSN08370A1 (en) | Tetrahydropyridothienopyrimidine compounds and methods of use thereof | |
UA99602C2 (ru) | Антитело, специфически связывающееся с jam-a, способное ингибировать пролиферацию опухолевых клеток | |
PL1776103T3 (pl) | Kompleksy rutenu do leczenia raków | |
WO2004058705A3 (en) | Inhibitors of the binding of chemokines i-tac or sdf-1 to the ccxckr2 receptor | |
TW200738236A (en) | Certain chemical entities, compositions, and methods | |
HK1116198A1 (en) | Antibodies binding to ephb4 for inhibiting angiogenesis and tumor growth | |
UA96426C2 (ru) | Выделенное человеческое или гуманизированное антитело, которое специфически связывается с il-13 | |
TW200621270A (en) | Novel use of nanogold for manufacturing medicaments for inhibiting metastasis of malignant tumors and growth of leukemic cells, and pharmaceutical compositions for inhibiting metastasis of malignant tumors and for treating leukemia comprising nanogold | |
TW200621265A (en) | Composition for treating tumor and/or preventing tumor transfer and recurrence | |
UA93875C2 (ru) | Выделенное химерическое или гуманизированное антитело, kotopoe специфически связывается c полипептидом tat10772 (ca125) | |
WO2006125139A3 (en) | Therapeutic uses of kallikreins | |
TW200504026A (en) | N-aryl-heteroaromatic products, compositions containing them and use thereof |